- Report
- October 2024
- 93 Pages
Global
From €3500EUR$4,065USD£3,072GBP
- Report
- March 2022
- 98 Pages
Global
From €3500EUR$4,065USD£3,072GBP
- Report
- November 2024
- 88 Pages
Global
From €3500EUR$4,065USD£3,072GBP
- Report
- November 2023
- 117 Pages
Global
From €3500EUR$4,065USD£3,072GBP
- Report
- June 2022
- 149 Pages
Global
From €1845EUR$2,000USD£1,564GBP
- Report
- May 2022
- 167 Pages
Global
From €2306EUR$2,500USD£1,956GBP
- Report
- February 2024
- 132 Pages
Global
From €876EUR$950USD£743GBP
- Report
- June 2022
- 198 Pages
Global
From €2231EUR$2,419USD£1,892GBP
€3188EUR$3,456USD£2,703GBP
- Report
- August 2022
United States
From €1789EUR$1,940USD£1,518GBP
- Report
- August 2022
Global
From €729EUR$790USD£618GBP
- Report
- August 2022
Global
From €913EUR$990USD£774GBP
- Report
- August 2021
Global
From €3680EUR$3,990USD£3,121GBP
The Hemophilia Drug market is a subset of the larger Hematological Drugs market. Hemophilia drugs are used to treat and prevent bleeding episodes in people with hemophilia, a rare genetic disorder. These drugs are typically administered intravenously or subcutaneously and are designed to replace the missing clotting factor in the patient's blood. Commonly used hemophilia drugs include recombinant factor VIII and IX, as well as plasma-derived factor VIII and IX.
The Hemophilia Drug market is highly competitive, with a number of companies offering a variety of products. Some of the major players in the market include Pfizer, Novo Nordisk, Bayer, Biogen, CSL Behring, and Shire. Show Less Read more
